The Journal of Organic Chemistry



Note

Subscriber access provided by ALBRIGHT COLLEGE

A Palladium-Catalyzed Cyclocarbonylation Approach to Thiadiazafluorenones. A Correction

Lucia Veltri, Roberta Amuso, Corrado Cuocci, Paola Vitale, and Bartolo Gabriele

J. Org. Chem., Just Accepted Manuscript • DOI: 10.1021/acs.joc.9b01043 • Publication Date (Web): 11 Jun 2019 Downloaded from http://pubs.acs.org on June 17, 2019

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.

is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

A Palladium-Catalyzed Cyclocarbonylation Approach to Thiadiazafluorenones.

A Correction

Lucia Veltri,*[†] Roberta Amuso,[†] Corrado Cuocci,[§] Paola Vitale,[‡] and Bartolo Gabriele^{*†}

⁺ Laboratory of Industrial and Synthetic Organic Chemistry (LISOC), Department of Chemistry and Chemical Technologies, University of Calabria, Via Pietro Bucci 12/C, 87036 Arcavacata di Rende (CS), Italy

[§] Institute of Crystallography, CNR, Via Amendola 122/O, 70124 Bari, Italy

⁺ Department of Pharmacy - Pharmaceutical Sciences, University of Bari "Aldo Moro", Via E. Orabona 4, Bari, 70125, Italy

lucia.veltri@unical.it; bartolo.gabriele@unical.it



Abstract

The palladium-catalyzed carbonylation of 2-(propynylthio)benzimidazoles bearing a terminal triple bond leads to 2-methyl-1-thia-4a,9-diazafluoren-4-ones, instead of the previously reported 3-methyl isomers, as unequivocally established by XRD analysis of a representative product. A correction is therefore provided here in order to rectify the previous erroneous assignment of the position of the methyl group. Moreover, the process has been generalized to substrates bearing an internal triple bond, which led to 3-alkyl-2-methyl-1-thia-4a,9-diazafluoren-4-ones, whose structure was confirmed by XRD analysis of two representative derivatives.

1-Thiadiazafluoren-4-one derivatives are polyheterocyclic compounds of particular interest, as they are known to possess significant pharmacological activities,^{1,2} including cardiotonic activity.² Their importance justifies the continuous interest in developing novel synthetic approaches starting from relatively simple and available substrates.³

In the course of our studies on carbonylation reactions leading to polyheterocyclic compounds, we investigated the reactivity of 2-(propynylthio)benzimidazoles bearing a terminal triple bond (**1a-f**) with carbon monoxide in the presence of the PdI₂/KI catalytic system under non-oxidative conditions. We published the results obtained, and assigned the structure of the products as 3-methyl-1-thia-4*a*,9-diazafluoren-4-ones (Scheme 1).⁴ We here reassign the structure of those products as the corresponding 2-methyl isomers, based on the results obtained with 2-(propynylthio)benzimidazoles bearing an internal triple bond and X-ray structural determination of representative products.

Scheme 1. Previously Reported Palladium-Catalyzed Cyclocarbonylation of 2-(Propynylthio)benzimidazoles Bearing a Terminal Triple Bond 1a-f⁴



We originally optimized the reactivity of **1a-f** and carried out the carbonylation reactions in EtOH at 100 °C for 3 h, under a 5/2 mixture of CO–CO₂ at 70 atm, in the presence of PdI₂ (2 mol%) and KI (1 equiv).⁴ Methyl-substituted 1-thia-4*a*,9-diazafluoren-4-ones were obtained, as confirmed by spectrometric and spectroscopic data, by an additive carbonylation process. A relatively simple mechanism, involving *N*-palladation followed by CO insertion, triple bond insertion, protonolysis, and isomerization, seemed in agreement with the formation of 3-methyl-substituted thiadiazafluorenones, as shown in Scheme S1 (Supporting Information).⁴

To further expand the synthetic scope of the process, we have investigated the reactivity of substrates bearing an internal triple bond. Surprisingly, however, the carbonylation reaction of 2-(pent-2-yn-1-ylthio)-1*H*-benzo[*d*]imidazole **3a** did not lead to the expected 3-propyl-substituted derivative, but to thiadiazofluorenone **4a** bearing a methyl group at C-2 and an ethyl group at C-3 (Scheme 2),⁵ as confirmed by XRD analysis (Figure 1).⁶

Scheme 2. Formation of 3-Ethyl-2-methyl-1-thia-4a,9-diazafluoren-4-one 4a from 2-(Pent-2-yn-1-ylthio)-



Figure 1. X-Ray Structure of 3-Ethyl-2-methyl-1-thia-4*a*,9-diazafluoren-4-one 4a, Showing the Atom Labelling

Scheme⁶

This unexpected result prompted us to reinvestigate the structure of the methyl-substituted products obtained starting from substrates bearing a terminal triple bond, which, by analogy to **4a**, could actually have corresponded to the 2-methyl-substituted isomers rather than the originally proposed⁴ 3-methyl-substituted compounds. A single crystal X-ray analysis of the product obtained from the carbonylation of 2-(prop-2-ynylthio)-1*H*-benzo[*d*]imidazole **1a**⁴ indeed confirmed that the methyl group occupies the C-2 rather than the C-3 position, and thus corresponds to 2-methyl-1-thia-4*a*,9-diazafluoren-4-one **2a**, as shown in Figure 2. This means that the structures of all products obtained in our original publication (with the methyl group at C-3)⁴ should be corrected to the corresponding 2-methyl-substituted isomers **2a–f**, as shown in Table S1 (Supporting Information).



Figure 2. X-Ray Structure of 2-Methyl-1-thia-4*a*,9-diazafluoren-4-one **2a**, Showing the Atom Labelling Scheme⁶

The process has then been generalized to other differently substituted substrates **3b–i**, bearing various alkyl groups on the triple bond and electron-withdrawing as well as π -donating groups on the aromatic ring. As can be seen from the results shown in Table 1, the reaction was quite general, and the corresponding 3-alkyl-2-methyl-1-thia-4*a*,9-diazafluoren-4-ones **4** were isolated in fair yields (50-60 %). The C-2 position of the methyl group was further confirmed by the XRD analysis of product **4f**, bearing two methoxy substituents of the aromatic ring (Figure 3).



Figure 3. X-Ray Structure of 3-Ethyl-6,7-Dimethoxy-2-methyl-1-thia-4a,9-diazafluoren-4-one 4f, Showing the

Atom Labelling Scheme⁶

Table 1. Synthesis 3-Alkyl-2-methyl-1-thia-4a,9-diazafluoren-4-ones 4a-i by Palladium-Catalyzed Carbonylation of 2

(Alkynylthio)benzimidazoles 3a-i Bearing an Internal Triple Bond^a



58 59

60



^{*a*} All reactions were carried out at 80 °C under 30 atm (at 25 °C) of CO, in MeOH as the solvent (substrate concentration: 0.2 mmol of **1** per mL of solvent), and in the presence of 2 mol% of PdI₂ and 1 equiv of KI. ^{*b*} Isolated yield, based on starting material **1**. ^{*c*} Mixture of regioisomers (~3/1 by ¹H NMR). ^{*d*} Mixture of regioisomers (~1.1/1 by ¹H NMR).

Mechanistically, formation of 2-methyl-substituted products **2a–f** (Table S1, Supporting Information) and **4a-i** (Table 1) must imply some kind of structural rearrangement. Most likely, this takes place by Pd(0)-promoted propargyl-allene rearrangement,⁷ occurring through formal Pd(0) attack to the terminal carbon of the triple bond, with elimination of a thiolate I and formation of the allenylpalladium intermediate II (Scheme 3). Formation of an iodide-stabilized palladium(0) species under our conditions may take place by the watergas shift reaction between PdI₂, CO and traces of water present in the reaction mixture, as already observed by us under similar conditions.⁸ Addition of the thiolate I to the allenic moiety of II then leads to palladacycle intermediate III. The latter undergoes carbon monoxide insertion to give IV, from which the final product is formed by reductive elimination (Scheme 3).

Scheme 3. Proposed Mechanistic Pathway for the Palladium-Catalyzed Cyclocarbonylation of 2-(Prop-2ynylthio)-1*H*-benzo[*d*]imidazoles 1a-f and 3a-i Leading to 2-Methyl-1-thia-4*a*,9-diazafluoren-4-ones 2a-f and 4a-i, respectively

 $PdI_2 + CO + H_2O \longrightarrow Pd(0) + 2 HI + CO_2$



ACS Paragon Plus Environment

To corroborate this mechanistic hypothesis, we carried out a cross-over experiment, by allowing to react an equimolar mixture of substrates **3d** and **3e** under the optimized conditions (Scheme 4). The GLC-MS analysis of the reaction mixture evidenced the formation of four products (**4a**, **4d**, **4e**, and **5**) (Scheme 4), deriving from the addition of the two different thiolates to the two different allenylpalladium complexes deriving from **3d** and **3e**, which is clearly in agreement with the proposed mechanism (Scheme 3).⁹

Scheme 4. Cross-over Experiment: Formation of a Mixture of Thiadiazafluorenones 4a, 4d, 4e, and 5 from Carbonylation of a Mixture of Substrates 3d and 3e



We also verified if free allenes (possibly deriving from protonolysis of complex II) were involved as intermediates in the formation of final bicyclic products. However, as shown in Scheme 5, the carbonylation of **3d** together with commercially available cyclohexylallene **6** only gave the diazafluorenone **4d** (49% yield) without any formation of the mixed product resulting from allene incorporation.¹⁰ This result strongly suggests that protonolysis of complex II to give a free allene does not occur in our process, and that, according to Scheme 3, this intermediate preferentially undergoes direct attack by thiolate I.

Scheme 5. Carbonylation of 3d in the presence of cyclohexylallene 6

> In conclusion, in this Note we have corrected the structure of the products obtained from Pdl₂/Klcatalyzed carbonylation of 2-(propynylthio)benzimidazoles bearing a terminal triple bond **1**. In fact, as confirmed by XRD analysis, 2-methyl-1-thia-4*a*,9-diazafluoren-4-ones **2** are formed, instead of the previously reported⁴ 3-methyl isomers. We have also extended the process to the use of substrates bearing an internal triple bond **3**, which, in a similar way, led to the corresponding 3-alkyl-2-methyl-1-thia-4*a*,9-diazafluoren-4ones **4**, as confirmed by XRD analysis. Product formation must ensue from some unexpected kind of structural rearrangement, most likely occurring through palladium-promoted propargyl-allene rearrangement to give a thiolate and an allenylpalladium intermediate, followed by thiolate addition to the central allenic carbon and cyclocarbonylation.

EXPERIMENTAL SECTION

General Experimental Methods. Solvents and chemicals were reagent grade and used without further purification. All reactions were analyzed by TLC on silica gel 60 F254 and by GLC using capillary columns with polymethylsilicone +5% phenylsilicone as the stationary phase. Column chromatography was performed on silica gel 60 (70–230 mesh) or alumina gel 90 (70–230 mesh). Evaporation refers to the removal of solvent under reduced pressure. Melting points are uncorrected. ¹H NMR and ¹³C NMR spectra were recorded at 25 °C on a 300 or 500 MHz spectrometers in CDCl₃, DMSO-*d*₆, or CD₃OD solutions with Me₄Si as the internal standard. ¹⁹F NMR spectra were recorded at 25 °C on a 500 MHz spectrometer in CDCl₃ solutions at 471 MHz with CF₂Br₂ or CFCl₃ as the internal standard. Chemical shifts (δ) and coupling constants (*J*) are given in ppm and Hz, respectively. IR spectra were taken with an FT-IR spectrometer. Mass spectra were obtained using a GC-MS apparatus at 70 eV ionization voltage. The HRMS spectra were taken on Q-TOF-MS mass spectrometer, equipped with an electrospray ion source (ESI) operated in dual ion mode. 10 µL of the sample solutions (CH₃OH) were introduced by continuous infusion at a flow rate of 200 L min⁻¹ with the aid of a syringe pump. Experimental conditions were performed as following: capillary voltage, 4000 V; nebulizer

The Journal of Organic Chemistry

pressure, 20 psi; flow rate of drying gas, 10 L/min; temperature of sheath gas, 325 C; flow rate of sheath gas, 10 L/min; skimmer voltage, 60 V; OCT1 RF Vpp, 750 V; fragmentor voltage, 170 V. The spectra data were recorded in the *m/z* range of 100–1000 Da in a centroid pattern of full-scan MS analysis mode. The MS/MS data of the selected compounds were obtained by regulating diverse collision energy (18–45 eV).

Preparation of Substrates 3a-i. 2-(Prop-2-ynylthio)-1*H*-benzo[*d*]imidazoles **3a-i**, bearing an internal triple bond, were prepared with the following procedure. To a solution of the 1H-imidazole-2-thione derivative (16.7 mmol) [1,3-dihydrobenzoimidazole-2-thione (commercially available): 2.50 g; 5,6-dimethyl-1,3dihydrobenzoimidazole-2-thione (commercially available): 2.97 g; 5,6-dichloro-1,3-dihydrobenzoimidazole-2-thione (commercially available): 3.65 g; 5.6-dimethoxy-1,3-dihydrobenzoimidazole-2-thione:⁴ 3.51 g; 5methoxy-1,3-dihydrobenzoimidazole-2-thione (commercially available): 3.00 g; 5-fluoro-1,3dihydrobenzoimidazole-2-thione:⁴ 2.81 g] in anhydrous acetone (100 mL), was added, under nitrogen, K₂CO₃ (2.3 g , 16.7 mmol,) and the 1-bromoalk-2-yne derivative (25.1 mmol) [1-bromopent-2-yne (commercially available): 3.69 g; 1-bromobut-2-yne (commercially available): 3.34 g; 1-bromohex-2-yne:¹¹ 4.04 g; 1bromooct-2-yne:¹² 4.75 g]. The mixture was stirred at room temperature for 20 h. After evaporation of the solvent, dichloromethane (30 mL) and water (30 mL) were sequentially added, and phases were separated. The aqueous phase was extracted again with dichloromethane (20 mL) and finally the collected organic phases were dried over Na₂SO₄. After filtration and evaporation of the solvent, products **3a-i** were purified by column chromatography on silica gel using as eluent: 9:1 hexane-AcOEt for 3b, 3d, 3h; 8:2 hexane-AcOEt for 3c; 7:3 hexane-AcOEt for 3a, 3e, 3f, 3g, 3i.

2-(*Pent-2-yn-1-ylthio*)-1*H-benzo*[*d*]*imidazole* (**3***a*). Yield: 2.75 g, starting from 2.50 g of 1,3dihydrobenzoimidazole-2-thione (76%). Colorless solid, mp = 139 – 141 °C. IR (KBr); v = 2972 (s), 2181 (vw), 1445 (s), 1402 (s), 1270 (m), 1228 (m), 980 (m), 737 (s) cm⁻¹. ¹H NMR (300 MHz, DMSO-*d*₆): δ = 12.74 (s, br, 1 H), 7.63 – 7.40 (m, 2 H), 7.24 – 7.13 (m, 2 H), 4.16 (t, *J* = 2.3 , 2 H), 2.16 (qt, *J* = 7.5, 2.3, 2 H), 1.00 (t, *J* = 7.5, 3 H); ¹³C{¹H}NMR (75 MHz, DMSO-*d*₆): δ = 149.0, 143.4 (br), 135.7 (br), 122.0, 117.6 (br), 111.0 (br), 85.5, 75.2, 20.8, 13.9, 12.0. GC/MS: *m/z* = 216 (M⁺, 77), 201 (100), 187 (27), 150 (27), 122 (42). HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₁₂H₁₂N₂SNa⁺ 239.0613; Found 239.0609.

2-(But-2-yn-1-ylthio)-1H-benzo[d]imidazole (**3b**). Yield: 2.70 g, starting from 2.50 g of 1,3dihydrobenzoimidazole-2-thione (80%). Colorless solid, mp = 169 – 171 °C; IR (KBr): v = 2972 (m, br), 2239 (vw), 1445 (m), 1402 (s), 1269 (m), 1229 (m), 980 (m) cm⁻¹. ¹H NMR (300 MHz, DMSO-*d*₆): δ = 12.59 (s, br, 1 H), 7.51 – 7.41 (m, 2 H), 7.18 – 7.09 (m, 2 H), 4.12 (q, *J* = 2.5, 2 H), 1.77 (t, *J* = 2.5, 3 H); ¹³C{¹H}NMR (75 MHz, DMSO-*d*₆): δ = 148.8, 121.5, 79.4, 74.8, 20.3, 3.2 (*Note:* the signals of quaternary carbons were too broad to be detected). GC-MS: *m/z* = 202 (M⁺, 100), 201 (72), 187 (31), 169 (81), 149 (42), 122 (77). HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₁₁H₁₀N₂SNa⁺ 225.0457; Found: 225.0451.

2-(Hex-2-yn-1-ylthio)-1H-benzo[d]imidazole (**3**c). Yield: 2.00 g, starting from 2.50 g of 1,3dihydrobenzoimidazole-2-thione (52%). Colorless solid, mp = 140 – 142 °C. IR (KBr): v = 2959 (m, br), 2234 (vw), 1441 (m), 1400 (m), 1269 (m), 1242 (m), 737 (s) cm⁻¹; ¹H NMR (300 MHz, CD₃OD): δ = 7.54 – 7.44 (m, 2 H), 7.24 – 7.15 (m, 2 H), 4.98 (s, br, 1 H), 4.03-3.98 (m, 2 H), 2.13 -2.02 (m, 2 H), 1.46 -1.29 (m, 2 H), 0.81 (t, J = 7.3, 3 H); ¹³C{¹H}NMR (75 MHz, CD₃OD): δ = 150.3, 140.4 (br), 123.5, 115.0 (b), 85.4, 75.7, 23.0, 22.5, 21.4, 13.6. GC–MS: *m/z* = 230 (M⁺, 60), 201 (100), 187 (24), 169 (28), 150 (28), 122 (29). HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₁₃H₁₄N₂SNa⁺ 253.0770; Found: 253.0769.

2-(Oct-2-yn-1-ylthio)-1H-benzo[d]imidazole (**3d**). Yield: 3.45 g, starting from 2.50 g of 1,3dihydrobenzoimidazole-2-thione (80%). Colorless solid, mp = 108 – 111 °C. IR (KBr): v = 2957 (m br), 2234 (w), 1445 (m), 1402 (s), 1267 (m), 1227 (m), 980 (m), 739 (s) cm⁻¹. ¹H NMR (500 MHz, DMSO- d_6): δ = 12.61 (s, br, 1 H), 7.50 – 7.41 (m, br, 2 H), 7.15 – 7.10 (m, 2 H), 4.12 (t, *J* = 2.3, 2 H), 2.12 (tt, *J* = 7.0, 2.3, 2 H), 1.36-1.31 (m, 2 H), 1.25 – 1.13 (m, 4 H), 0.77 (t, *J* = 7.0, 3 H); ¹³C{¹H}NMR (125 MHz, DMSO- d_6): δ = 148.6, 121.5, 83.7, 75.7, 30.2, 27.7, 21.5, 20.5, 17.9, 13.7 (*Note:* the signals of two quaternary carbons were too broad to be detected); GC-MS: *m/z* = 258 (M⁺, 100), 202 (97), 201 (100), 187 (14), 169 (14), 143 (41). HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₁₅H₁₈N₂SNa⁺ 281.1083; Found: 281.1085.

5,6-Dimethyl-2-(pent-2-yn-1-ylthio)-1H-benzo[d]imidazole (3e). Yield: 2.45 g, starting from 2.97 g of 5,6-dimethyl-1,3-dihydrobenzoimidazole-2-thione (60%). Colorless solid, mp = 164 - 166 °C. IR (KBr): v = 2974 (m), 2232 (vw), 1449 (m), 1391 (s), 1227 (m), 982 (m); ¹H NMR (300 MHz, DMSO-*d*₆): δ = 7.26 (s, 2 H), 4.12 (t, *J* = 2.2, 2 H), 2.28 (s, 6 H), 2.14 (qt, *J* = 7.5, 2.2, 2 H), 0.99 (t, *J* = 7.5, 3 H) (*Note:* the NH signal was too broad

to be detected). ¹³C{¹H}NMR (75 MHz, DMSO-*d*₆): δ = 147.1, 137.4, 130.2, 114.1, 85.2, 75.0, 20.8, 19.9, 13.6, 11.7 (*Note:* the signals of two quaternary carbons were too broad to be detected); GC-MS: *m/z* = 244 (M⁺, 100), 243 (23), 229 (53), 171 (6). HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₁₄H₁₆N₂SNa⁺ 267.0926; Found: 267.0925.

5,6-Dimethoxy-2-(pent-2-yn-1-ylthio)-1H-benzo[d]imidazole (**3f**). Yield: 3.46 g, starting from 3.51 g of 5.6dimethoxy-1,3-dihydrobenzoimidazole-2-thione (75%). Colorless solid, mp = 102 – 105 °C; IR (KBr): v = 2950 (m), 2234 (vw), 1393 (s), 1331 (s), 1200 (s), 1138 (s), 1007 (m), 849 (m) cm⁻¹; ¹H NMR (300 MHz, CD₃OD): δ = 7.05 (s, 2 H), 4.95 (s, br); 3.90 (t, *J* = 2.4, 2 H), 3.85 (s, 6 H), 2.10 (qt, *J* = 7.5, 2.4, 2 H), 0.98 (t, *J* = 7.5, 3 H); ¹³C{¹H}NMR (75 MHz, CD₃OD): δ = 148.6, 146.9, 97.8 (br), 86.9, 75.0, 56.8, 23.4, 14.1, 13.0 (*Note:* the signal of a quaternary carbon was too broad to be detected); GC-MS: *m/z* = 276 (M⁺, 100), 261 (43), 243 (26), 209 (14), 174 (5). HRMS (ESI-TOF) m/z : [M + Na]⁺ Calcd for C₁₄H₁₆N₂O₂SNa⁺ 299.0825; Found: 299.0825.

6-Methoxy-2-(pent-2-yn-1-ylthio)-1H-benzo[d]imidazole (**3g**). Yield: 3.29 g, starting from 3.00 g of 5methoxy-1,3-dihydrobenzoimidazole-2-thione (80%). Colorless solid, mp = 112 – 116 °C; IR (KBr): v = 2875 (m), 2230 (vw), 1628 (m), 1393 (s), 1204 (s), 1161 (s), 1034 (m), 980 (m), 806 (s) cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ = 7.48 (d, *J* = 8.8, 1 H), 7.08 (d, *J* = 2.3, 1 H), 6.87 (dd, *J* = 8.8, 2,3, 1 H), 4.01 (t, *J* = 2.4, 2 H), 3.82 (s, 3 H), 2.12 (qt, *J* = 7.5, 2.4, 2 H), 1.04 (t, *J* = 7.5, 3 H) (*Note:* the NH signal was too broad to be detected); ¹³C{¹H}NMR (75 MHz, CDCl₃); δ = 156.4, 148.1, 139.5 (br), 134.3 (br), 115.3, 111.9, 97.2, 86.5, 74.1, 55.8, 22.5, 13.6, 12.5; GC-MS: *m/z* = 246 (M⁺, 100), 231 (51), 217 (25), 174 (15), 120 (18). HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₁₃H₁₄N₂OSNa⁺ 269.0719; Found: 269.0717.

5,6-Dichloro-2-(pent-2-yn-1-ylthio)-1H-benzo[d]imidazole (3h). Yield: 3.33 g, starting from 3.65 g of 5,6-dichloro-1,3-dihydrobenzoimidazole-2-thione (70%). Yellow solid. mp = 188 - 193 °C. IR (KBr): v = 2920 (m), 2234 (vw), 1377 (s), 1319 (m), 1096 (m), 961 (m), 868 (m) cm⁻¹; ¹H NMR (300 MHz, DMSO-*d*₆): δ = 7.74 (s, 2 H), 4.15 (t, *J* = 2.4, 2 H), 2.16 (qt, *J* = 7.5, 2.4, 2 H), 1.00 (t, *J* = 7.5, 3 H) (*Note:* the NH signal was too broad to be detected); ¹³C{¹H}NMR (75 MHz, DMSO-*d*₆): δ = 152.5, 124.0, 114.8 (br), 85.3, 74.8, 20.4, 13.6, 11.8 (*Note:* the signal of a quaternary carbon was too broad to be detected); GC-MS: *m/z* = 288 [(M+4)⁺, 13], 286 [(M+2)⁺,

69], 285 [(M+1)⁺, 21)], 284 (M⁺, 100), 271 (27), 269 (39), 257 (55), 255 (76), 220 (39), 167 (32). HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₂H₁₁Cl₂N₂S⁺ 285.0015; Found: 285.0015.

G-Fluoro-2-(pent-2-yn-1-ylthio)-1H-benzo[d]imidazole (**3i**). Yield: 1.56 g, starting from 2.81 g of 5-fluoro-1,3-dihydrobenzoimidazole-2-thione: 2.81 (40%). Colorless solid, mp = 175 – 177 °C; IR (KBr): v = 2914 (m, br), 2237 (vw), 1397 (s), 1142 (s), 988 (m), 845 (s), 799 (s) cm⁻¹; ¹H NMR (300 MHz, DMSO-*d*₆): δ = 12.79 (s, br, 1 H), 7.62-7.20 (m, 2 H), 7.01 (t, *J* = 9.7, 1 H), 4.18-4.12 (m, 2 H), 2.22 – 2.11 (m, 2 H), 1.01 (t, *J* = 7.5, 3 H). ¹³C{¹H}NMR (75 MHz, DMSO-*d*₆): δ = 158.2 (d, *J* = 233.9, C-6 bonded to F), 150.7 (tautomer A), 149.5 (tautomer B), 144.0 (tautomer A or B), 140.2 (tautomer B or A), 135.5 (tautomer A or B), 132.1 (tautomer B or A), 118.1 (tautomer A or B), 110.9 (tautomer B or A), 109.7 (d, *J* = 25.3, C-5 or C-7, tautomer A or B), 109.3 (d, *J* = 25.3, C-5 or C-7, tautomer B or A), 103.3 (d, *J* = 24.3, C-7 or C-5, tautomer A or B), 97.2 (d, *J* = 25.5, C-7 or C-6, tautomer B or A), 85.1, 74.9, 20.4, 13.6, 11.7 (*Note:* some carbon signals were doubled owing to slow tautomerization of the imidazole ring). ¹⁹F NMR (471 MHz, DMSO-*d*₆): δ = -120.0 (s, tautomer A or B), -121.4 (s, tautomer B or A). GC-MS: *m/z* = 234 (M⁺, 76), 219 (100), 205 (32), 168 (27), 140 (47), 108 (37). HRMS (ESI-TOF) m/z: [M + Na]* Calcd for C₁₂H₁₁FN₂SNa* 257.0519; Found: 257.0513.

General Procedure for the Synthesis of Thiadiazafluorenones 4a–i (Table 1). A 35 mL stainless steel autoclave was charged in the presence of air with PdI_2 (5.8 mg, 1.61×10^{-2} mmol), KI (133 mg, 0.81 mmol), MeOH (4 mL), and the 2-prop-2-ynylthiobenzimidazole (0.81 mmol; **3a**: 175 mg; **3b**: 164 mg; **3c**: 187 mg; **3d**: 209 mg; **3e**: 198 mg; **3f**: 224 mg; **3g**: 200 mg; **3h**: 231 mg; **3i**: 190 mg). The autoclave was purged at room temperature several times with CO under stirring (5 atm) and eventually pressurized with CO₂ (30 atm). After being stirred at 80 °C for 3 h, the autoclave was cooled, degassed and opened. After evaporation of the solvent, products **4** were purified by column chromatography on neutral alumina using 98:2 hexane-AcOEt as eluent.

3-Ethyl-2-methyl-1-thia-4a,9-diazafluoren-4-one (*4a*). Yield: 119 mg, starting from 175 mg of **3a** (60%) (Table 1, entry 1). Colorless solid, mp = 132 – 134°C. IR (KBr): v = 1675 (s), 1475 (s), 1432 (s), 1358 (m), 1313 (m), 1148 (m), 760 (m) cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ = 8.57 (d, *J* = 8.1), 7.74 (d, *J* = 8.1), 7.50-7.44 (m, 1 H), 7.44-7.38 (m, 1 H), 2.76 (q, *J* = 7.5, 2 H), 2.43 (s, 3 H), 1.18 (t, *J* = 7.5, 3 H); ¹³C{¹H}NMR (125 MHz, CDCl₃):

δ = 160.4, 146.2, 142.4, 140.7, 131.6, 127.8, 125.7, 123.8, 118.4, 116.1, 21.3, 20.6, 13.0. GC-MS: *m/z* = 244 (M⁺, 100), 229 (51), 211 (16), 201 (16). HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₁₃H₁₂N₂OSNa⁺ 267.0563; Found: 267.0557.

2,3-Dimethyl-1-thia-4a,9-diazafluoren-4-one (**4b**). Yield: 103 mg, starting from 164 mg of **3b** (55%) (Table 1, entry 2). Colorless solid, mp = $178 - 183^{\circ}$ C. IR (KBr). v = 1674 (s), 1474 (m), 1435 (m), 1354 (w), 1312 (m), 1150 (m), 768 (s) cm⁻¹. ¹HNMR (300 MHz, CDCl₃): $\delta = 8.59$ (d, J = 8.0), 7.73 (d, J = 7.7), 7.50-7.30 (m, 2 H), 2.36 (s, 3 H), 2.21 (s, 3 H). ¹³C{¹H}NMR (75 MHz, CDCl₃): $\delta = 160.7$, 146.1, 142.3, 140.6, 131.4, 125.7, 123.8, 121.8, 118.3, 116.0, 21.3, 13.4. GC-MS: m/z = 230 (M⁺, 100), 201 (27), 169 (15), 150 (15). HRMS (ESI-TOF) m/z: [M - H]⁻ Calcd for [C₁₂H₉N₂OS]⁻ 229.0441; Found: 229.0452.

2-Methyl-3-propyl-1-thia-4a,9-diazafluoren-4-one (**4c**). Yield: 119 mg, starting from 187 mg of **3c** (57%) (Table 1, entry 3). Colorless solid, mp = 111 – 112°C. IR (KBr): v = 1684 (s), 1466 (s), 1431 (s), 1350 (s), 1311 (s), 1152 (m), 746 (s) cm⁻¹. ¹HNMR (300 MHz, CDCl₃): δ = 8.57 (d, *J* = 8.0), 7.74 (d, *J* = 7.8, 1 H), 7.52-7.35 (m, 2 H), 2.70 (t, *J* = 7.6, 2 H), 2.43 (s, 3 H), 1.59 (sext, *J* = 7.6, 2 H), 1.03 (t, *J* = 7.6, 3 H). ¹³C{¹H}NMR (125 MHz, CDCl₃): δ = 160.5, 146.2, 142.3, 141.0, 131.5, 126.4, 125.7, 123.8, 118.4, 116.1, 29.8, 22.0, 20.9, 14.1. GC-MS: *m/z* = 258 (M⁺, 96), 243 (14), 229 (100), 201 (16), 143 (12). HRMS (ESI-TOF) m/z: [M – H]⁻ Calcd for C₁₄H₁₃N₂OS⁻ 257.0754; Found: 257.0764.

2-Methyl-3-pentyl-1-thia-4a,9-diazafluoren-4-one (**4d**). Yield: 128 mg, starting from 209 mg of **3d** (55%) (Table 1, entry 4). Colorless solid, mp = 56 – 58°C. IR (KBr): v = 1684 (s), 1474 (s), 1443 (s), 1383 (s), 1315 (m), 1225 (m), 1155 (m), 760 (s) cm⁻¹. ¹HNMR (300 MHz, CDCl₃): δ = 8.51 (d, *J* = 7.6, 1 H), 7.68 (d, *J* = 7.9), 7.44-7.28 (m, 2 H), 2.62 (t, *J* = 7.8, 2 H), 2.34 (s, 3 H), 1.57-1.22 (m, 6 H), 0.87 (t, *J* = 6.5, 3 H). ¹³C{¹H}NMR (125 MHz, CDCl₃): δ = 160.4, 146.1, 142.3, 140.8, 131.4, 126.5, 125.6, 123.7, 118.3, 116.0, 31.8, 28.4, 27.9, 22.5, 20.8, 14.0. GC-MS: *m/z* = 286 (M⁺, 47), 229 (37), 202 (31), 137 (100). HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₁₆H₁₈N₂OSNa⁺: 309.1032; Found: 309.1036.

2,6,7-Trimethyl-3-ethyl-1-thia-4a,9-diazafluoren-4-one (*4e*). Yield: 124 mg, starting from 198 mg of **3e** (56%) (Table 1, entry 5). Colorless solid, mp = 154 – 158°C. IR (KBr): v = 1667 (s), 1477 (m), 1442 (s), 1350 (s),

1169 (m), 883 (m), 768 (m) cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ = 8.27 (s, 1 H), 7.43 (s, 1 H), 2.70 (q, *J* = 7.4, 2 H), 2.38 (s, 3 H), 2.36 (s, 6 H), 1.15 (t, *J* = 7.4, 3 H). ¹³C{¹H}NMR (75 MHz, CDCl₃): δ = 160.2, 144.9, 140.8, 140.4, 134.7, 132.9, 129.7, 127.4, 118.3, 116.1, 21.2, 20.52, 20.46, 13.0. GC/MS: *m/z* = 272 (M⁺, 100), 257 (44), 239 (13), 229 (19). HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₁₅H₁₆N₂OSNa⁺ 295.0876; Found: 295.0871.

3-Ethyl-6,7-dimethoxy-2-methyl-1-thia-4a,9-diazafluoren-4-one (**4***f*). Yield: 123 mg, starting from 224 mg of **3f** (50%) (Table 1, entry 6). Colorless solid, mp = 167 – 169°C. IR (KBr): v = 1667 (s), 1462 (s), 1427 (s), 1373 (m), 1318 (s), 1007 (m), 841 (m), 756 (m) cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ = 8.13 (s, 1 H), 7.20 (s, 1 H), 4.01 (s, 3 H), 3.97 (s, 3 H) 2.76 (q, *J* = 7.5, 2 H), 2.44 (s, 3 H), 1.18 (t, *J* = 7.5, 3 H). ¹³C{¹H}NMR (75 MHz, CDCl₃): δ = 160.5, 148.6, 147.1, 143.6, 140.8, 136.3, 127.2, 125.1, 100.1, 98.7, 56.4, 56.2, 21.3, 20.6, 13.1. GC/MS: *m/z* = 304 (M⁺, 100), 289 (60), 261 (9), 167 (32). HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₁₅H₁₆N₂O₃SNa⁺ 327.0774; Found: 327.0767.

Mixture of Regioisomers 3-*Ethyl*-7-*methoxy*-2-*methyl*-1-*thia*-4*a*,9-*diazafluoren*-4-*one* (*A*) *and* 3-*Ethyl*-6*methoxy*-2-*methyl*-1-*thia*-4*a*,9-*diazafluoren*-4-*one* (*B*) (**4***g*; *A*/*B* ratio about 3.0, *by* ¹*HNMR*). Yield: 127 mg, starting from 200 mg of **3***g* (57%) (Table 1, entry 7). Colorless solid, mp = 114 – 119°C. IR (KBr): v = 1670 (s), 1477 (s), 1431 (s), 1358 (m), 1018 (m), 845 (m), 764 (m) cm⁻¹; ¹H NMR (300 MHz,CDCl₃): δ = 8.40 (d, *J* = 8.9, 1 H, B), 8.09 (d, *J* = 2.4, 1 H, A), 7.59 (d, *J* = 8.8, 1 H, A), 7.17 (d, *J* = 2.3, 1 H, B), 7.05 (dd, *J* = 8.8, 2.4, 1 H, A), 6.97 (dd, *J* = 8.9, 2.3, 1 H, B), 3.90 (s, 3 H, A), 3.87 (s, 3 H, B), 2.72 (q, *J* = 7.4, 2 H, A+B), 2.40 (s, 3 H, A+B), 1.16 (t, *J* = 7.4, 3 H, A+B); ¹³C{¹H}NMR (75 MHz, CDCl₃): δ = 160.6 (A), 160.0 (B), 158.3 (B), 157.0 (A), 146.4 (B), 144.2 (A), 143.6 (B), 141.0 (A), 140.3 (B), 136.6 (A), 132.1 (A), 127.6 (B), 127.3 (A), 125.8 (B), 118.7 (A), 116.4 (B), 115.3 (A), 112.7 (B), 101.1 (B), 99.4 (A), 55.92 (A), 55.89 (B), 21.3 (A+B), 20.6 (A+B), 13.1 (A+B); GC/MS [A]: *m/z* = 274 (M⁺, 100), 259 (55), 231 (18), 180 (10), 165 (11). GC/MS [B]: *m/z* = 274 (M⁺, 100), 259 (56), 231 (17), 180 (10), 165 (11). HRMS (ESI - TOF) m/z: [M + Na]⁺ Calcd for C₁₄H₁₄N₂O₂SNa⁺ 297.0668; Found: 297.0663.

6,7-Dichloro-3-ethyl-2-methyl-1-thia-4a,9-diazafluoren-4-one (*4h*). Yield: 150 mg, starting from 231 mg of **3h** (59%) (Table 1, entry 8). Colorless solid, mp = 200 – 202°C. IR (KBr): v = 1670 (s), 1466 (m), 1427 (s), 1350 (m), 914 (m), 872 (m) cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ = 8.63 (s, 1 H), 7.75 (s, 1 H), 2.75 (q, *J* = 7.5, 2 H), 2.46 (s, 3 H), 1.17 (t, *J* = 7.5, 3 H). ¹³C{¹H}NMR (75 MHz, CDCl₃): δ = 159.7, 148.1, 141.5, 141.4, 130.3, 129.9, 127.84,

127.82, 119.4, 117.3, 21.3, 20.7, 12.9. GC/MS: *m/z* = 316 [(M+4)⁺, 13], 314 [(M+2)⁺, 65], 312 (M⁺, 100), 299 (22), 297 (30), 279 (17), 277 (18), 271 (11), 269 (16). HRMS (ESI-TOF) m/z: [M + H]⁺ calcd for C₁₃H₁₁Cl₂N₂OS⁺ 312.9964; Found: 312.9949.

Mixture of Regioisomers 3-Ethyl-6-fluoro-2-methyl-1-thia-4a,9-diazafluoren-4-one (A) and 3-Ethyl-7fluoro-2-methyl-1-thia-4a,9-diazafluoren-4-one (B) (**4i**; A/B ratio about 1.1, by ¹HNMR).Yield: 121 mg, starting from 190 mg of **3i** (57%) (Table 1, entry 9). Colorless solid, mp = 107 – 109°C. IR (KBr): v = 1670 (s), 1468 (s), 1437 (s), 1358 (m), 1130 (m), 845 (m), 814 (m) cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ = 8.46 (dd, *J* = 8.9, 5.0, 1 H, A), 8.24 (dd, *J* = 8.9, 2.4, 1 H, B), 7.63 (dd, *J* = 8.9, 4.8, 1 H, B), 7.36 (dd, *J* = 8.9, 2.3, 1 H, A), 7.18 (td, *J* = 8.9, 2.4, 1 H, B), 7.09 (dd, *J* = 8.9, 2.3, 1 H, A), 2.79-2.67 (m, 2 H, A+B), 2.43 (s, 3 H, A), 2.43 (s, 3 H, B), 1.22-1.12 (m, 3 H, A+B); ¹³C{¹H}NMR (75 MHz, CDCl₃): δ = 160.9 (d, *J* = 242.6, A), 160.09 (B), 159.95 (A), 159.6 (d, *J* = 241.6, B), 147.8 (A+B), 146.2 (B), 143.2 (d, *J* = 12.8, A), 141.0 (d, *J* = 28.9, B), 138.67 (A or B), 138.65 (B or A), 131.4 (d, *J* = 14.2, B), 128.8 (A), 127.6 (d, *J* = 22.0, A), 118.9 (d, *J* = 9.9, B), 116.7 (d, *J* = 9.9, A), 113.8 (d, *J* = 25.1, B), 111.7 (d, *J* = 25.2, A), 104.5 (d, *J* = 24.8, A), 103.3 (d, *J* = 29.6, B), 21.28 (A+B), 20.64 (A), 20.60 (B), 12.99 (A+B). ¹⁹F NMR (471 MHz, CD₃Cl): δ = -115.8 (s, A), -117.4 (s, B); GC/MS (A + B): *m/z* = 262 (M⁺, 100), 247 (52), 229 (16), 219 (21), 168 (9). HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₁₃H₁₁FN₂OSNa⁺ 285.0468; found: 285.0468.

Cross-over Experiment (Scheme 4). A 35 mL stainless steel autoclave was charged in the presence of air with PdI₂ (11.6 mg, 3.22×10^{-2} mmol), KI (267 mg, 1.61 mmol), MeOH (8 mL), **3d** (208.7 mg, 0.81 mmol) and **3e** (197.6 mg, 0.81 mmol). The autoclave was purged at room temperature several times with CO under stirring (5 atm) and eventually pressurized with CO₂ (30 atm). After being stirred at 80 °C for 20 h, the autoclave was cooled, degassed and opened. The resulting crude inseparable mixture was analyzed by GLC and LC-MS, which evidenced the formation of **4a**, **4d**, **4e** and **5** in a ratio **4a**: **4d**: **4e**: **5** = 1: 1.2: 3: 1.9 (determined by GLC).⁹ GC/MS (5): m/z = 314 (M⁺, 100), 271 (14), 257 (46), 230 (48), 178 (16), 137 (73).

Carbonylation of 3d in the Presence of Cyclohexylallene (Scheme 5). A 35 mL stainless steel autoclave was charged in the presence of air with PdI_2 (8.3 mg, 2.30×10^{-2} mmol), KI (191.24 mg, 1.15 mmol), MeOH (5.8 mL), **3d** (148.8 mg, 0.58 mmol) and cyclohexylallene **6** (commercially available; 70.4 mg, 0.58 mmol). The

autoclave was purged at room temperature several times with CO under stirring (5 atm) and eventually pressurized with CO₂ (30 atm). After being stirred at 80 °C for 20 h, the autoclave was cooled, degassed and opened. The crude mixture was analyzed in GLC to determinate the cyclohexylallene conversion (54%). After evaporation of the solvent, the crude mixture was purified by column chromatography on neutral alumina (98:2 hexane-AcOEt as eluent) affording **4d** in 49% yield (81.8 mg).¹⁰

Supporting Information. Scheme S1, Table S1, X-Ray data for compounds **2a**, **4a**, and **4f**. Copy of HRMS, ¹H NMR, ¹³C{¹H}NMR, and ¹⁹F NMR spectra for Substrates **3a-i** and Products **4a-i**.

Acknowledgments

The X-ray laboratory for single-crystal diffraction at the Dipartimento di Scienze della Terra and Geoambientali, University of Bari "Aldo Moro", was funded by Fondo Europeo per lo Sviluppo Regionale (FESR), Fondo di rotazione (FDR) Programma Operativo Nazionale per le Regioni dell'Obiettivo 1 – Ricerca Scientifica, Sviluppo Tecnologico, Alta Formazione 2000-2006.

The XRPD laboratory at the Dipartimento di Scienze della Terra and Geoambientali, University of Bari "Aldo Moro", was funded by Potenziamento Strutturale PONa3_00369 "Laboratorio per lo Sviluppo Integrato delle Scienze e delle Tecnologie dei Materiali Avanzati e per dispositivi innovativi (SISTEMA)".

References

(1) (a) Garaliene, V.; Labanauskas, L.; Brukštus, A. Effect of 1-Acyl-5,6-dialkoxy-2alkylthiobenzo[d]imidazoles on the Action, Potential Duration and Isometric Contraction in Guinea Pig Atrium

Activated by Carbachol and in Guinea Pig Heart Papillary Muscles. *Drug Res.* **2006**, *56*, 282-287. (b) Brukshtus, A. B.; Garalene, V. N.; Sirvidite, A. R.-R.; Daukshas, V. K. Synthesis and Cardiotonic Activity of 2-Alkylthio-1acyl-5, 6-dimethoxybenzimidazoles and their Cyclic Analogs. *Pharm. Chem. J.* **1994**, *28*, 392-395. (c) Brukshtus, A. B.; Garalene, V. N.; Sirvidite, A. R.-R.; Daukshas, V. K. Synthesis and Cardiotonic activity of 2-Alkyl-thio-1-acyl-5,6-methylene(or Ethylene)dioxy-Benzimidazoles and their Cyclic Analogs. *Pharm. Chem. J.* , *26*, 851-854.

(2) Crossley, R. (John Wyeth & Brother Limited, Maidemhead, England). Preparation of 2,3-Dihydrothiazolo- and Thiazinobenzimidazoles as Antiulcer and Antihypersecretion Agents. *US Pat.* 4,873,237 (1989).

(3) See, for examples: (a) Khalil, A. K. *Phosphorus Sulfur Silicon Relat. Elem.* Phase-Transfer Catalyzed Alkylation and Acylation of 2-Mercapto-5-Methyl-1*H*-Benzimidazole. **2007**, *182*, 815-823. (b) Britsun, V. N.; Lozinskii, M. O. Synthesis of 2-Aryl-2,3-dihydro-4*H*-[1,3]thiazino[3,2-*a*]benzimidazol-4-ones and 7-Aryl-2,3,6,7-tetrahydro-5*H*-imidazo[2,1-*b*]-1,3-thiazin-5-ones. *Chem. Heterocycl. Compds.* **2003**, *39*, 960-964. (c) Bell, S. C.; Wei, P. H. L. Syntheses of Heterocyclic Fused Thiazole Acetic Acids. *J. Med. Chem.* **1976**, *19*, 524-530.

(4) Veltri, L.; Paladino, V.; Plastina, P.; Gabriele, B. A Palladium Iodide-Catalyzed Cyclocarbonylation Approach to Thiadiazafluorenones. *J. Org. Chem.* **2016**, *81*, 6106–6111.

(5) The conditions reported in Scheme 3 ensued from an optimization study of the operative parameters (data not shown).

(6) Detailed X-ray structural determination data as well as the CIFs can be found in the Supporting Information.

(7) For a recent example, see: Li, Q.-H.; Jeng, J.-Y.; Gau, H.-M. Highly Efficient Synthesis of Allenes from Trimethylaluminum Reagent and Propargyl Acetates Mediated by a Palladium Catalyst. *Eur. J. Org. Chem.* **2014**, 7916-7923.

(8) Chiusoli, G.P.; Costa, M.; Cucchia, L.; Gabriele, B.; Salerno, G.; Veltri, L. Carbon Dioxide Effect on Palladium-Catalyzed Sequential Reactions with Carbon Monoxide, Acetylenic Compounds and Water. *J. Mol. Catal. A:Chem.* **2003**, *204*, 133-142.

(9) The relative amounts of products **4d**, **4e**, **4a**, and **5** were 1: 1.2: 3: 1.9 (determined by GLC). All attempts to isolate at the pure state mixed product **5** failed, owing to the complexity of the reaction mixture; however, its GLC-MS spectrum was compatible with the assigned structure. We thank the Associate Editor, Prof. Scott D. Rychnovsky, for suggesting us to carry out this experiment.

(10) The cyclohexylallene conversion was 54% (determined by GLC analysis of the reaction mixture); partial decomposition occurred with formation of chromatographically immobile materials, which were not investigated further). We thank the Associate Editor and a referee for suggesting us to carry out such an experiment.

(11) Carless, H. A. J.; Batten, R. J. Photosensitized Oxidation of Model Unsaturated Lipid System – (4*Z*, 7*Z*)-Undeca-4,7-diene and (4*Z*)-Undec-4-en-7-yne. *J. Chem. Soc., Perkin Trans.* 1 **1987**, 1999-2007.

(12) Rosenberger, M. (Hoffmann-La Roche Inc.). Synthesis of SRS-Active Compounds. *U.S. Pat.* US4311645 (1982).